Posted in Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority April 14, 2026 Pharmaceutical Business Review The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. RegulatoryOncologyRead full story